title: PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
abstract: Antibodies targeting programmed death 1 (PD-1) help prevent tumor cells from escaping immune-mediated destruction. We conducted this systematic review and meta-analysis to gain insight into the efficacy of PD-1 antibodies for the treatment of melanoma. Five trials involving 2,828 adult patients were included in this meta-analysis. In patients with previously untreated or refractory melanoma, treatment with PD-1 antibodies significantly improved the six-month progression-free survival (PFS) (HR 0.55, 95% CI 0.50-0.60, P<0.00001) and the overall response rate (OR 3.89, 95% CI 3.12-4.83, P<0.00001). This meta-analysis indicated that anti-PD-1 treatment might provide a significant survival benefit in patients with melanoma. In addition, we found that patients treated with nivolumab reported significantly fewer treatment-related adverse events (OR 0.74, 95% CI 0.57-0.97, P = 0.03) than those treated with other agents, but there was a dose-dependent increase in the frequency of adverse events in patients treated with pembrolizumab.
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Zhijuan
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Department of Nephrology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Xing
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Zhifeng
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Yiming
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Fang
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
authors.forename: Bing
authors.initials: B
authors.lastname: Xu
authors.affiliation: Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.|State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, People's Republic of China.|Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, and Department of Stem Cells and Regenerative Medicine, Peking Union Medical College, Tianjin, People's Republic of China.
authors.forename: Mingzhe
authors.initials: M
authors.lastname: Han
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005076:Exanthema / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D005221:Fatigue / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D015870:Gene Expression; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009325:Nausea / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D011537:Pruritus / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000096142:Cutaneous Malignant Melanoma
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab